Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/20/2017 09/21/2017 09/22/2017 09/25/2017 09/26/2017 Date
3.425(c) 3.625(c) 3.575(c) 3.35(c) 3.5 Last
80 000 0 850 84 060 0 Volume
+1.48% +5.84% -1.38% -6.29% +4.48% Change
More quotes
Financials ( GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -0,10 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 33,50
Capi. / Sales2017 2,42x
Capi. / Sales2018 1,80x
Capitalization 9,91 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
07/25 PROTEOME SCIENCES : Interim results for the six months ended 30 June 2017
06/30 PROTEOME SCIENCES : Stroke Diagnostic Presentation at EuroMedLab 2017 – Re..
06/15 THERMO FISHER SCIENTIFIC : Recognizes Tandem Mass Tag Grant Award Winners at ASM..
04/25 PROTEOME SCIENCES : AGM Statement and Result of AGM
04/25 PROTEOME SCIENCES : Trading Remains In Line With Expectations
04/03 PROTEOME SCIENCES : Appoints Richard Dennis Chief Commercial Officer
04/03 PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
03/31 PROTEOME SCIENCES : Annual Report and Accounts 2016
03/28 PROTEOME SCIENCES : Says "Much Yet To Do" As Loss Narrows In 2016
03/28 PROTEOME SCIENCES : Preliminary results for the year ended 31 December 2016 Noti..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/24Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
07/25Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
07/25Proteome Sciences : Interim results for the six months ended 30 June 2017  
06/30Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
06/30Proteome Sciences : Stroke Diagnostic Presentation at EuroMedLab 2017 &nd.. 
More tweets
Qtime:5
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Technical analysis trends PROTEOME SCIENCES PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Non-Executive Chairman
Stefan Fuhrmann Finance Director
Ian H. Pike Executive Director & Chief Scientific Officer
Roger Steven McDowell Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-39.09%13
AMGEN27.65%135 931
CELGENE CORPORATION25.22%113 394
GILEAD SCIENCES16.76%109 188
REGENERON PHARMACEUTICALS17.88%46 949
VERTEX PHARMACEUTICALS102.39%37 591